IDXX PE Ratio & Valuation,Is IDXX Overvalued

IDXX Relative Valuation

IDXX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IDXX is overvalued; if below, it's undervalued.

Historical Valuation

IDEXX Laboratories Inc (IDXX) is now in the Fair zone, suggesting that its current forward PE ratio of 49.70 is considered Fairly compared with the five-year average of 50.57. The fair price of IDEXX Laboratories Inc (IDXX) is between 517.70 to 792.45 according to relative valuation methord.

Relative Value

Fair Zone

517.70-792.45

Current Price：700.55

Fair

49.70

35.60

EV/EBITDA

IDEXX Laboratories Inc. (IDXX) has a current EV/EBITDA of 35.60. The 5-year average EV/EBITDA is 35.37. The thresholds are as follows: Strongly Undervalued below 18.62, Undervalued between 18.62 and 27.00, Fairly Valued between 43.74 and 27.00, Overvalued between 43.74 and 52.12, and Strongly Overvalued above 52.12. The current Forward EV/EBITDA of 35.60 falls within the Historic Trend Line -Fairly Valued range.

39.23

EV/EBIT

IDEXX Laboratories Inc. (IDXX) has a current EV/EBIT of 39.23. The 5-year average EV/EBIT is 39.45. The thresholds are as follows: Strongly Undervalued below 20.20, Undervalued between 20.20 and 29.83, Fairly Valued between 49.08 and 29.83, Overvalued between 49.08 and 58.70, and Strongly Overvalued above 58.70. The current Forward EV/EBIT of 39.23 falls within the Historic Trend Line -Fairly Valued range.

12.34

IDEXX Laboratories Inc. (IDXX) has a current PS of 12.34. The 5-year average PS is 11.30. The thresholds are as follows: Strongly Undervalued below 6.34, Undervalued between 6.34 and 8.82, Fairly Valued between 13.78 and 8.82, Overvalued between 13.78 and 16.26, and Strongly Overvalued above 16.26. The current Forward PS of 12.34 falls within the Historic Trend Line -Fairly Valued range.

45.04

P/OCF

IDEXX Laboratories Inc. (IDXX) has a current P/OCF of 45.04. The 5-year average P/OCF is 45.07. The thresholds are as follows: Strongly Undervalued below 20.94, Undervalued between 20.94 and 33.00, Fairly Valued between 57.14 and 33.00, Overvalued between 57.14 and 69.20, and Strongly Overvalued above 69.20. The current Forward P/OCF of 45.04 falls within the Historic Trend Line -Fairly Valued range.

50.64

P/FCF

IDEXX Laboratories Inc. (IDXX) has a current P/FCF of 50.64. The 5-year average P/FCF is 53.07. The thresholds are as follows: Strongly Undervalued below 24.89, Undervalued between 24.89 and 38.98, Fairly Valued between 67.16 and 38.98, Overvalued between 67.16 and 81.25, and Strongly Overvalued above 81.25. The current Forward P/FCF of 50.64 falls within the Historic Trend Line -Fairly Valued range.

IDEXX Laboratories Inc (IDXX) has a current Price-to-Book (P/B) ratio of 35.87. Compared to its 3-year average P/B ratio of 33.90 , the current P/B ratio is approximately 5.84% higher. Relative to its 5-year average P/B ratio of 47.46, the current P/B ratio is about -24.40% higher. IDEXX Laboratories Inc (IDXX) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.76%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 1.61% , the current FCF yield is about -100.00% lower.

35.87

P/B

Median3y

33.90

Median5y

47.46

1.71

FCF Yield

Median3y

1.76

Median5y

1.61

Competitors Valuation Multiple

The average P/S ratio for IDXX's competitors is , providing a benchmark for relative valuation. IDEXX Laboratories Inc Corp (IDXX) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 13.29%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of IDXX increased by 69.44% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 36.54 to 55.56.

The secondary factor is the Revenue Growth, contributed 13.29%to the performance.

Overall, the performance of IDXX in the past 1 year is driven by P/E Change. Which is more unsustainable.

13.29%

975.54M → 1.11B

Revenue Growth

4.11%

23.87 → 24.85

Margin Expansion

52.04%

36.54 → 55.56

P/E Change

69.44%

413.44 → 700.55

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is IDEXX Laboratories Inc (IDXX) currently overvalued or undervalued?

What is IDEXX Laboratories Inc (IDXX) fair value?

IDXX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of IDEXX Laboratories Inc (IDXX) is between 517.70 to 792.45 according to relative valuation methord.

How does IDXX's valuation metrics compare to the industry average?

What is the current P/B ratio for IDEXX Laboratories Inc (IDXX) as of Dec 16 2025?

As of Dec 16 2025, IDEXX Laboratories Inc (IDXX) has a P/B ratio of 35.87. This indicates that the market values IDXX at 35.87 times its book value.

What is the current FCF Yield for IDEXX Laboratories Inc (IDXX) as of Dec 16 2025?

As of Dec 16 2025, IDEXX Laboratories Inc (IDXX) has a FCF Yield of 0.00%. This means that for every dollar of IDEXX Laboratories Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for IDEXX Laboratories Inc (IDXX) as of Dec 16 2025?

As of Dec 16 2025, IDEXX Laboratories Inc (IDXX) has a Forward P/E ratio of 49.70. This means the market is willing to pay $49.70 for every dollar of IDEXX Laboratories Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for IDEXX Laboratories Inc (IDXX) as of Dec 16 2025?

As of Dec 16 2025, IDEXX Laboratories Inc (IDXX) has a Forward P/S ratio of 0.00. This means the market is valuing IDXX at $0.00 for every dollar of expected revenue over the next 12 months.

IDXX Valuation